$CMPX News

Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026

Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Compass Therapeutics (CMPX) Stock Fair Value Falls After Tovecimig Regulatory Concerns

Craig-Hallum Maintains Buy on Compass Therapeutics, Lowers Price Target to $8

Compass Therapeutics: A Promising, But Shrinking, Window Of Opportunity

Citizens Maintains Market Outperform on Compass Therapeutics, Lowers Price Target to $4

Guggenheim Maintains Buy on Compass Therapeutics, Lowers Price Target to $4

Wedbush Downgrades Compass Therapeutics to Neutral, Lowers Price Target to $1

HC Wainwright & Co. Maintains Buy on Compass Therapeutics, Lowers Price Target to $12

CMPX Plunge Wipes Out $104M After FDA Demands Fresh Trial For Cancer Drug — Wedbush Sees Another 19% Downside

Compass Therapeutics Craters, FDA Pushes Survival-Trial Demand for Cancer Drug

CMPX Stock Crashes To Over 2-Year Lows — Why FDA Wants Another Cancer Therapy Trial Before Key Marketing Filing

Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback

Piper Sandler Maintains Overweight on Compass Therapeutics, Raises Price Target to $6

Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update

Compass Therapeutics Q2 EPS $(0.13) Misses $(0.11) Estimate

Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026

Compass Therapeutics Abstract Accepted For Oral Presentation At Upcoming European Society For Medical Oncology Congress

Compass Therapeutics: A 50% Price Cut Hiding A Regulatory Mispricing Opportunity

Here’s Why Citizens Maintains a Buy on Compass Therapeutics (CMPX)